Ms. Barbara Vermeulen reports

MEDIPHARM LABS PUBLISHES STUDY INVESTIGATING MEDICAL CANNABIS IMPACTS ON ANXIETY AND DEPRESSION OUTCOMES IN FIBROMYALGIA PATIENTS

Medipharm Labs Corp.'s wholly owned subsidiary Harvest Medicine Inc.'s (HMED) study entitled, "Self-Reported Effects of Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series" has been published in the peer-reviewed American Journal of Endocannabinoid Medicine.

The retrospective study was led by HMED and reviewed data from 805 patients who indicated fibromyalgia as a primary reason for seeking medical cannabis and had a minimum of one follow-up assessment. The majority of patients (76.1 per cent) reported using CBD (cannabidiol) oil, which aligns with the current practice guidelines for authorizing medical cannabis as an adjuvant therapy for managing chronic pain.

The primary findings from the present study include a significant reduction in all three scores measuring depression, anxiety and illness severity between baseline and first follow-up:

• Seventy-five per cent of patients saw a decrease in their self-reported illness severity, which may include chronic pain, insomnia and fatigue.
• Anxiety scores were improved in 22 per cent of those patients reporting mild-moderate severity, and in 48 per cent of patients reporting severe anxiety.
• Twenty-seven per cent of patients reporting mild-medium depression noted a reduction in symptoms, while 48 per cent of patients reporting severe depression showed a reduction in PHQ-9 score.

The validated study data show that medical cannabis may play an effective role in the management of fibromyalgia and associated symptoms of depression and anxiety, and that additional, similar studies are recommended.

"Since 2017, Harvest Medicine's primary objective is to improve the quality of patients' lives by providing access to medical cannabis and offering the highest standard of medical care with a scientifically informed approach," commented Barbara Vermeulen, director of Harvest Medicine. "We will continue to advocate for patients to maintain access to physician guided consultations and education, with the goal of reducing stigma among health care professionals and advancing patient outcomes."

Details on the study can be viewed on American Journal of Endocannabinoids website.

Medipharm remains focused on investing in clinical research and supporting the development of future cannabis-derived pharmaceutical drugs. Consistent with this commitment, the company continues to supply sponsors and investigators with cannabis-derived study drugs, placebos, and other services and assistance as may be required during the course of the studies.

In addition to institutionally led studies, the company is also providing API (active pharmaceutical ingredients) and clinical trial material to various pharmaceutical companies for commercial projects involving cannabis-derived drugs. The timelines for both institutional and industry research are long by nature with positive outcomes uncertain.

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a good manufacturing practices certified facility with ISO standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies, and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

We seek Safe Harbor.